168 related articles for article (PubMed ID: 1846309)
1. Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis.
Berger U; McClelland RA; Wilson P; Greene GL; Haussler MR; Pike JW; Colston K; Easton D; Coombes RC
Cancer Res; 1991 Jan; 51(1):239-44. PubMed ID: 1846309
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A
Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
[TBL] [Abstract][Full Text] [Related]
3. Steroid receptors in breast cancer.
Desombre ER
Monogr Pathol; 1984; (25):149-74. PubMed ID: 6377047
[TBL] [Abstract][Full Text] [Related]
4. Estrogen and progesterone receptor status of primary breast cancer: relationship with the pattern of first metastasis and survival.
Bhatavdekar JM; Patel DD; Karelia NH; Trivedi SN; Shah NG; Vora HH; Ghosh N; Balar DB
Neoplasma; 1992; 39(6):349-52. PubMed ID: 1491724
[TBL] [Abstract][Full Text] [Related]
5. Significance of 1,25-dihydroxyvitamin D3 receptor in primary breast cancers.
Eisman JA; Suva LJ; Martin TJ
Cancer Res; 1986 Oct; 46(10):5406-8. PubMed ID: 3019526
[TBL] [Abstract][Full Text] [Related]
6. Relationship of presence of progesterone receptors to prognosis in early breast cancer.
Pichon MF; Pallud C; Brunet M; Milgrom E
Cancer Res; 1980 Sep; 40(9):3357-60. PubMed ID: 7427948
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
8. Progesterone receptor status of breast cancer metastases.
Branković-Magić M; Janković R; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
J Cancer Res Clin Oncol; 2002 Jan; 128(1):55-60. PubMed ID: 11862473
[TBL] [Abstract][Full Text] [Related]
9. Biochemically estrogen receptor-negative, progesterone receptor-positive breast carcinoma. Immunocytochemical hormone receptors and prognostic factors.
Keshgegian AA
Arch Pathol Lab Med; 1994 Mar; 118(3):240-4. PubMed ID: 8135626
[TBL] [Abstract][Full Text] [Related]
10. A new look at the prognostic value of the estrogen, progesterone and epidermal growth factor receptors in breast cancer tissue.
Skasko E; Paszko Z; Mazur S
Neoplasma; 2005; 52(1):10-7. PubMed ID: 15739020
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with prognosis in human breast cancer. IV. Progesterone receptors and clinical factors.
Macías A; Pascual MR; Pérez R; Lage A
Neoplasma; 1983; 30(5):593-601. PubMed ID: 6656963
[TBL] [Abstract][Full Text] [Related]
12. Progesterone and estrogen receptors as prognostic variables in breast cancer.
Mason BH; Holdaway IM; Mullins PR; Yee LH; Kay RG
Cancer Res; 1983 Jun; 43(6):2985-90. PubMed ID: 6850609
[TBL] [Abstract][Full Text] [Related]
13. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.
Keshgegian AA; Cnaan A
Arch Pathol Lab Med; 1996 Oct; 120(10):970-3. PubMed ID: 12046611
[TBL] [Abstract][Full Text] [Related]
15. [Cancer of the breast and the receptor status].
Buonomo O; Serao A; Muggianu A; Guglielmelli E; Davoli E; Amori A
G Chir; 1991 Apr; 12(4):274-7. PubMed ID: 1911078
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment.
Colleoni M; Viale G; Zahrieh D; Pruneri G; Gentilini O; Veronesi P; Gelber RD; Curigliano G; Torrisi R; Luini A; Intra M; Galimberti V; Renne G; Nolè F; Peruzzotti G; Goldhirsch A
Clin Cancer Res; 2004 Oct; 10(19):6622-8. PubMed ID: 15475452
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic value of estrogen and progesterone receptors in the operable breast cancer: results of a uni- and multifactorial analysis].
Chevallier B; Heintzman F; Asselain B; Dauce JP; Bastit P; Graic Y; Brunelle P; Basuyau JP; Comoz M
Bull Cancer; 1988; 75(1):23-36. PubMed ID: 3359056
[TBL] [Abstract][Full Text] [Related]
18. [The estrogen receptor/progesterone receptor quotient as an index of the transcriptional activity of estrogen receptors in breast cancer].
Navarro MA; Díez Gibert O; Fernández-Montolí ME; Rosel P; Bonnin MR
Med Clin (Barc); 1995 May; 104(18):681-2. PubMed ID: 7769876
[TBL] [Abstract][Full Text] [Related]
19. Expression of epidermal growth factor receptor in breast cancer, from early stages to advanced disease.
Nesković-Konstantinović Z; Nikolić-Vukosavljević D; Branković-Magić M; Kanjer K; Gavrilović D; Mitrović L; Borojević N; Vukotić D; Spuzić I
J Exp Clin Cancer Res; 1999 Sep; 18(3):347-55. PubMed ID: 10606181
[TBL] [Abstract][Full Text] [Related]
20. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
